SIGA Technologies has reached the final stages of its clinical trial for a drug that could cure small pox.
The final stages come on the heels of a receipt from the U.S. Food and Drug Administration (FDA) to continue the human study of tecovirimat for concurrence on dosage.
The drug will also work on other orthopoxvirus diseases, such as smallpox.
“We are pleased to receive FDA concurrence on dosage for our clinical safety studies and look forward to the future development and distribution of this critical antiviral,” SIGA CEO Eric Rose said.
The concurrence on dosage gives SIGA the instruction to follow through on phase three, which will include an expanded trial on humans. The drug will be taken orally.
SIDA is a company that develops drugs for medical needs that are serious, yet unmet. The tecovirimat is also known as ST-246.